Search
Folic acid
go.drugbank.com/drugs/DB00158ApprovedInvestigationalNutraceuticalVet approved[L5744] In order to function within the body, folic acid must first be reduced by the enzyme dihydrofolate reductase (DHFR) into the cofactors dihydrofolate (DHF) and tetrahydrofolate (THF). … More specifically, folic acid is required by the body for the synthesis of purines, pyrimidines, and methionine before incorporation into DNA or protein.
Mixtures: B Compound 50mg Tab, Folic Acid 1mg With C 20mgTianeptine
go.drugbank.com/drugs/DB09289InvestigationalAsia (including Singapore) and Latin America as “Stablon” and “Tatinol” but it is not available in Australia, Canada, New Zealand, the U.K. or the U.S. … Tianeptine was discovered and patented by The French Society of Medical Research in the 1960s [L2946].
Hepatitis A Vaccine
go.drugbank.com/drugs/DB10989ApprovedInvestigationalagainst the disease caused by infection with this virus. … [A199182] Known by several trade names, such as Havrix and Twinrix, the Hepatitis A vaccine has been formulated for immunization against hepatitis A virus (HAV) infection and safely confers strong protection
Clotrimazole
go.drugbank.com/drugs/DB00257ApprovedInvestigationalVet approvedThis drug is a broad spectrum antimycotic or antifungal agent. Clotrimazole's antimycotic properties were discovered in the late 1960s . Clotrimazole falls under the imidazole category of azole antifungals, possessing broad-spectrum anti...
Mixtures: MYKOFUNGIN 3 200MG+10MG/G, MYKOFUNGIN 3 200MG+10MG/GProducts: Myclo Crm 10mg, Myclo Crm 50mgTetracycline
go.drugbank.com/drugs/DB00759ApprovedInvestigationalVet approvedWithdrawnTetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. … It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site.
Nirsevimab
go.drugbank.com/drugs/DB16258ApprovedInvestigational[L44146] Nirsevimab was also approved by Health Canada on April 19, 2023 and by the FDA in July 17, 2023 for the same indication.[L46392,L47461] … [A254571,L44146] On November 2022, nirsevimab was approved by the EMA for the prevention of RSV lower respiratory tract disease in newborns and infants.
Rilpivirine
go.drugbank.com/drugs/DB08864ApprovedInvestigational[A31331] Rilpivirine was developed by Tilbotec, Inc. and FDA approved on May 20, 2011.
Mixtures: COMPLERA FILM-COATED TABLET 200MG/25MG/300MGRavulizumab
go.drugbank.com/drugs/DB11580ApprovedInvestigational[A244465] It was later approved by the European Commission on July 2, 2019, for the same indications.[L39710] Ravulizumab is also used to treat myasthenia gravis. … [A244465] Ravulizumab was first approved by the FDA on December 21, 2018, for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome in children and adults.
Cinoxacin
go.drugbank.com/drugs/DB00827ApprovedWithdrawnSynthetic antimicrobial related to oxolinic acid and nalidixic acid and used in urinary tract infections.
Posaconazole
go.drugbank.com/drugs/DB01263ApprovedInvestigationalVet approvedPosaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients.
Products: Posaconazol Sandoz 40mg/ml - Suspension zum Einnehmen